Cassava Sciences, Inc., a clinical-stage biotechnology company focused on developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, announced that the topline results from ...

Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...

It’s Alzheimer’s drug Simufilam did not show a significant reduction in ... Dave Bartosiak's technical analysis approach adds depth to our understanding Cassava Sciences’ stock chart. By paying ...

Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.

Cassava Sciences' Alzheimer's drug simufilam failed key trial endpoints, leading to a stock plunge. See why SAVA stock is at risk of delisting or merger.

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummeted ~90%. See why I changed my ...

Cassava Sciences announced that the phase 3 trial of its Alzheimer's drug, simufilam, did not meet its primary endpoints.

Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...

I spent four crazy years writing about Cassava Sciences, Adam Feuerstein writes. Yesterday, the story ended exactly as many ...

NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are ...

H.C. Wainwright analyst Vernon Bernardino downgraded Cassava Sciences (SAVA) to Neutral from Buy without a price target after the company ...

A pair of rival hospitals in Indiana walked back their merger application, shortly before the state was expected to rule on ...